Biosimilar to Simponi® (golimumab)

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries is executing a successful 'Pivot to Growth' strategy, transitioning from a generics-centric model to an innovation-driven biopharmaceutical company. This shift has yielded three consecutive years of revenue growth, driven by its specialty portfolio in CNS disorders and a burgeoning biosimilars pipeline. The company's integrated model, spanning complex generics, API manufacturing, and novel drug development, provides a durable competitive moat and positions it to address both affordability and unmet medical needs globally.

About Organon

Organon's mission is to improve the health of women throughout their lives by addressing critical gaps in reproductive health, contraception, fertility, and menopause. The company has achieved immediate global scale with a portfolio in over 140 markets, leveraging its heritage brands and deep commercial expertise. Its strategy focuses on maximizing the value of its established therapeutic portfolio, expanding access to biosimilars, and advancing a targeted pipeline in women's health to drive sustainable growth.

Therapeutic Areas